

Attorney Docket No.: 4814.214-US

1651
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Charlotte Johansen Serial No.: To Be Assigned

Confirmation No: 5761 Group Art Unit: 1651

Filed: March 23, 2001 Examiner: To be assigned

For: Antimicrobia 1 Peroxidase Compositions

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box Sequence
Commissioner for Patents
Washington, DC 20231

RECEIVED
JUL 12 2001
TECH CENTER 1600/2900

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to Comply with Sequence Rules
2. Sequence Listing
3. Copy of Notice to Comply with Sequence Rules


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence
Commissioner for Patents
Washington, DC 20231

on July 6, 2001.

Julie Tabarovsky
(name of person mailing paper)

J. Tabarovsky
(signature of person mailing paper)



Attorney Docket No.: 4814.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Charlotte Johansen Serial No.: To Be Assigned

Confirmation No: 5761 Group Art Unit: 1651

Filed: March 23, 2001 Examiner: To be assigned

For: Antimicrobia 1 Peroxidase Compositions

RECEIVED
JUL 12 2001
TECH CENTER 1600/2900

**AMENDMENT AND RESPONSE TO NOTICE TO FILE MISSING PARTS
AND TO NOTICE TO COMPLY WITH SEQUENCE RULES**

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Sequence Rules dated May 14, 2001, please amend the above-captioned application as follows

IN THE SPECIFICATION:


Please delete the previously submitted Sequence Listing and renumber the subsequent pages accordingly. Please insert the attached Sequence Listing (pages 1-2) at the end of the specification.

REMARKS

Applicants enclose herewith the Sequence Listing for the above-captioned application. The computer-readable form in this application is identical with that filed in Application Serial No. 09/174,956 filed October 19, 1998. In accordance with 37 CFR 1.821(e), please use the computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. The content of the attached paper entitled "SEQUENCE LISTING" and of the diskette filed in the parent application is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Elias J. Lambiris", written over a horizontal line.

Date: July 6, 2001

Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

RECEIVED
JUL 12 2001
TECH CENTER 1600/2900